Fly News Breaks for December 2, 2019
Dec 2, 2019 | 06:42 EDT
Citi analyst Joel Beatty lowered his price target for Madrigal Pharmaceuticals to $166 from $173 while maintaining a Buy rating on the shares. He continues to believe that Madrigal's Resmetirom is one of the most promising agents in later-stage development for the treatment of earlier-stage nonalcoholic steatohepatitis, particularly those with dyslipidemia. The analyst expects the stock to trade up as the ongoing Phase 3 study progresses, possibly completing enrollment in 2020.
News For MDGL From the Last 2 Days
There are no results for your query MDGL